Patents Represented by Attorney Lawrence A. Nielsen
-
Patent number: 5466711Abstract: A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.Type: GrantFiled: May 20, 1992Date of Patent: November 14, 1995Assignee: Burroughs Wellcome Co.Inventors: Victoria S. Latter, Winston E. Gutteridge, Alan T. Hudson
-
Patent number: 5453510Abstract: 1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockage), in comparison with the known mixture of geometrical and optical isomers.Type: GrantFiled: July 10, 1992Date of Patent: September 26, 1995Assignee: Burroughs Wellcome Co.Inventors: Derek A. Hill, Geoffrey L. Turner
-
Patent number: 5447956Abstract: Use of Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo [1,2-6]pyridazin-2-yl]carbamate or pharmaceutically acceptable salt to treat lymphocytic leukemia is disclosed.Type: GrantFiled: July 8, 1994Date of Patent: September 5, 1995Assignee: Burroughs Wellcome Co.Inventor: Simon T. Hodgson
-
Patent number: 5432166Abstract: The use of 1-(.beta.-D-arabinofuranosyl)-5-propynyluracil or a pharmaceutically acceptable salt or physiologically labile ester thereof for lowering serum cholesterol, particularly low density lipoprotein cholesterol levels in a human subject.Type: GrantFiled: February 11, 1993Date of Patent: July 11, 1995Assignee: Burroughs Wellcome Co.Inventors: Richard W. Peck, John Posner, Kenneth Powell
-
Patent number: 5427798Abstract: A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.Type: GrantFiled: August 12, 1993Date of Patent: June 27, 1995Assignee: Burroughs Wellcome Co.Inventors: Jennie Sue G. Ludwig, William L. Bass, Jr., Joel E. Sutton, Jr.
-
Patent number: 5422373Abstract: Diaryl urea compounds having anti-atherosclerosis activity are disclosed. Preferred compounds include the compounds 1-[4-(1,2-dimethoxyethoxy)benzyl-3-(2,4-dimethoxyphenyl)-l-heptylumea and 1-heptyl-3-(2,4-dimethoxyphenyl)-l-[4-(2-methoxyethoxymethoxy)-benzyl]urea .Type: GrantFiled: March 23, 1993Date of Patent: June 6, 1995Assignee: Burroughs Wellcome Co.Inventor: Karl W. Franzmann
-
Patent number: 5420156Abstract: 1-Ethylphenoxathiin 10,10-dioxide (I) ##STR1## inhibits monoamine oxidase-A and is useful in the treatment of disorders such as depression.Type: GrantFiled: December 8, 1993Date of Patent: May 30, 1995Assignee: Burroughs Wellcome Co.Inventors: Morton Harfenist, Daniel P. C. McGee, Helen L. White, Barrett R. Cooper
-
Patent number: 5399580Abstract: Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring in place of the conventional sugar residue, particularly those in which the 2-, 5- and 6-positions of the benzimidazole base are substituted by halogen, have activity against hepatitis B virus infections.Type: GrantFiled: September 27, 1993Date of Patent: March 21, 1995Assignee: Burroughs Wellcome Co.Inventor: Susan M. Daluge
-
Patent number: 5395853Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein m is 0 or 1;W is hydrogen, a C.sub.1-16 straight, branched, or cyclic alkyl group, or a C.sub.2-16 straight, branched, or cyclic alkenyl or alkynyl group, orPh(CH.sub.2).sub.n -- where Ph is phenyl and n is an integer of from 0 to 2, the phenyl group being optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen, orR.sup.1 NHCO-- where R.sup.1 is hydrogen or a C.sub.1-6 alkyl group, orR.sup.2 CONH-- where R.sup.2 is hydrogen or a C.sub.1-6 alkyl group; ##STR2## Y is --(CH.sub.2).sub.q, where q is an integer of from 1 to 3, or --CH.dbd.CH-- (E or Z);Z is a C.sub.Type: GrantFiled: November 24, 1993Date of Patent: March 7, 1995Assignee: Burroughs Wellcome Co.Inventors: William P. Jackson, Clifford J. Harris, Richard J. Arrowsmith, John G. Dann, Kevin J. O'Connor, Robert F. G. Booth
-
Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia
Patent number: 5380759Abstract: Methyl N-[6-(3,4,5-trimethoxybenzloxy) imidazo [1,2-6]pyridazin-2-yl]carbamate is disclosed which is used to treat leukemia.Type: GrantFiled: September 17, 1993Date of Patent: January 10, 1995Assignee: Burroughs Wellcome Co.Inventor: Simon T. Hodgson -
Patent number: 5370880Abstract: The invention relates to a controlled release pharmaceutical formulation for oral administration which comprises discrete units comprising acrivastine or a salt thereof coated with a mixture containing:a) a copolymer or polymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids andb) ethyl cellulose,and a process for preparing such formulations.Type: GrantFiled: September 8, 1993Date of Patent: December 6, 1994Assignee: Burroughs Wellcome Co.Inventors: Harry P. Jones, Robert J. Mackey, Michael J. D. Gamlen
-
Patent number: 5371219Abstract: Compounds of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted carbocyclic or heterocyclic aryl group, or an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R.sup.2 represents an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group or an optionally substituted carbocyclic or heterocyclic aryl or aralkyl group; R.sup.3 represents a hydrogen atom or an alkyl group; and either X represents an oxygen or sulphur atom, a group --CH.sub.2 -- or a group NR.sup.4 where R.sup.4 represents a hydrogen atom of a C.sub.1-4 alkyl group; and Y represents a group --CH.sub.2 -- or --CH.sub.2 CH.sub.2 -- or X--Y together represent the group --CH.dbd.CH--; and salts and physiologically functional derivatives thereof are useful in the treatment of tumours. Processes for preparing the compounds, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in the treatment of tumours are also described.Type: GrantFiled: September 17, 1993Date of Patent: December 6, 1994Assignee: Burroughs Wellcome Co.Inventor: Simon T. Hodgson
-
Patent number: 5358970Abstract: This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.Type: GrantFiled: August 12, 1993Date of Patent: October 25, 1994Assignee: Burroughs Wellcome Co.Inventors: Michael D. Ruff, Sanyasi R. Kalidindi, Joel E. Sutton, Jr.
-
Patent number: 5318974Abstract: The present invention relates to amino acid esters of pyrimidine and purine nucleosides containing an acyclic side chain, and their use in medical therapy, particularly the treatment of herpes virus infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.Type: GrantFiled: March 5, 1992Date of Patent: June 7, 1994Assignee: Burroughs Wellcome Co.Inventor: Lilia M. Beauchamp
-
Patent number: 5310762Abstract: A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.Type: GrantFiled: November 22, 1991Date of Patent: May 10, 1994Assignee: Burroughs Wellcome Co.Inventors: Victoria S. Latter, Winston E. Gutteridge, Alan T. Hudson
-
Patent number: 5290814Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein m is 0 or 1;W is hydrogen, a C.sub.1-16 straight, branched, or cyclic alkyl group, or a C.sub.2-16 straight, branched, or cyclic alkenyl or alkynyl group, or Ph(CH.sub.2).sub.n -- where Ph is phenyl and n is an integer of from 0 to 2, the phenyl group being optionally substituted by one or more atoms or groups independently selected from halogen, hydroxy, nitro, C.sub.1-4 alkoxy and C.sub.1-4 alkyl wherein one or more of the hydrogen atoms in said alkyl group is optionally replaced by halogen, or R.sup.1 NHCO-- where R.sup.1 is hydrogen or a C.sub.1-6 alkyl group, or R.sup.2 CONH-- where R.sup.2 is hydrogen or a C.sub.1-6 alkyl group; X is ##STR2## where A is halogen; Y is --(CH.sub.2).sub.q, where q is an integer of from 1 to 3, or --CH.dbd.CH-- (E or Z);Z is a C.sub.Type: GrantFiled: November 5, 1992Date of Patent: March 1, 1994Assignee: Burroughs Wellcome Co.Inventors: William P. Jackson, Clifford J. Harris, Richard J. Arrowsmith, John G. Dann, Kevin J. O'Connor, Robert F. G. Booth
-
Patent number: 5241107Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.1 (I)or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters, thereof; acid addition salts thereof; wherein Ar is a C.sub.15-18 fused tetracarbocyclic ring system containing 3 or 4 aromatic rings or a C.sub.17-22 fused pentacarbocyclic ring system containing 4, or 5 aromatic rings, or a substituted derivative thereof; the ring system Ar should be planar or deviate only slightly from planarity. Thus, the ring system contains a maximum of two non-aromatic carbon atoms which may be in the same ring, in which case they are adjacent, or in different rings;Ar is not perylene, fluoranthene, chrysene, pyrene, or triphenylene;R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen;R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.Type: GrantFiled: November 14, 1985Date of Patent: August 31, 1993Assignee: Burroughs Wellcome Co.Inventor: Kenneth W. Bair
-
Patent number: 5240937Abstract: This invention describes the preparation and use of anticonvulsant agents. In particular, triazolopyridine compounds are described which have utility in the treatment of epilepsy in mammals.Type: GrantFiled: May 1, 1992Date of Patent: August 31, 1993Assignee: Burroughs Wellcome Co.Inventor: James L. Kelley
-
Patent number: D346102Type: GrantFiled: December 21, 1992Date of Patent: April 19, 1994Assignee: Burroughs Wellcome Co.Inventor: Brian L. Ogden
-
Patent number: D376847Type: GrantFiled: December 21, 1992Date of Patent: December 24, 1996Assignee: Burroughs Wellcome Co.Inventors: Martin R. Alden, Alexander McCall